Allergan, plc
 |
|
| Public | |
| Traded as | : AGN S&P 100 Component S&P 500 Component |
| Industry | Branded and generic pharmaceuticals, and pharmaceutical research and development. |
| Founded | Est 2015 through the acquisition of Allergan, Inc by Actavis, Plc |
| Founder | Allen Chao, Ph.D. and David Hsia, Ph.D. |
| Headquarters | Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States. |
|
Number of locations
|
40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide. |
|
Area served
|
~100 countries |
|
Key people
|
Brenton L. Saunders Chairman and CEO |
| Products | Branded and generic pharmaceuticals |
| Revenue |
 US$ 15.07 billion (2015) |
|
US$ 1.090 billion (2014) |
|
 -US$ 1.630 billion (2014) |
|
| Total assets |
US$ 52.529 billion (2014) |
| Total equity |
US$ 28.3355 billion (2014) |
|
Number of employees
|
30,000 (June 2015) |
| Website | www |
Allergan, Plc is a multi-national pharmaceutical that produces branded and generic drugs, and performs pharmaceutical research and development. It was formed on February 18, 2015, when the company formerly known as Actavis, Plc changed its name. This was completed as of June 15, 2015. Actavis, Plc then became Actavis which now forms the American Generics division of the company.
After the acquisition of Allergan, Inc by Actavis, Plc, the new company made its first acquisition on July 6, when the company acquired start-up, Oculeve, for $125 million. On July 7 the company announced it would acquire Merck & Cos late stage CGRP migraine portfolio, as well as two experimental drugs (MK-1602 and MK-8031) for $250 million. In July, Allergan agreed to sell off its small molecule generic drug business, Actavis, to Teva Pharmaceutical Industries for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares), a transaction to be completed in Q1 2016. A day later, the company announced it would acquire Naurex Inc for $560 million with more tied to regulatory milestones. In September the company announced it would acquire ophthalmic device start-up AqueSys for $300 million plus future sums tied to approval/sales milestones. In November the company acquired aesthetic device company Northwood Medical Innovation. Two days after announcing the record breaking deal with Pfizer, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder, rabies and obsessive compulsive disorder.
In late October 2015, The Wall Street Journal reported that merger talks between Allergan and Pfizer were in early phases, with Pfizer approaching Allergan due to an industry-wide drop in share prices. Any merger with Allergan would then also give Pfizer the ability to re-domicile to Ireland, taking advantage of its lower tax rates. On 23 November 2015, the two companies announced their intention to merge for an approximate sum of $160 billion making this the largest pharmaceutical deal ever and the third largest merger in history. As part of the deal, Pfizer CEO Ian Read would have remained CEO and Chairman of the combined company (to be called Pfizer Plc), with Allergan CEO, Brent Saunders, becoming President and Chief operating officer. As part of the deal Allergan shareholders will receive 11.3 shares of the company, with Pfizer shareholders receiving one. Pfizer discontinued the acquisition on 5 April 2016, after the Obama administration announced its plan to move ahead with a resolution banning this form of tax avoidance, known as a tax inversion. Pfizer will pay Allergan a breakup fee of $150 million.
...
Wikipedia